The use of remdesivir (Veklury, Gilead) can have significant benefits for immunocompromised people with COVID-19, reducing mortality by 30%.
Using the treatment promptly in these patients can provide a significant survival benefit, and is effective across all virus variants, said the authors of a recent report (Clin Infect Dis 2023;77[12]:1626-1634).
“Upon conclusion of the public health emergency, SARS-CoV-2 remains at least as consequential as influenza in our daily lives,”